-+ 0.00%
-+ 0.00%
-+ 0.00%

ULTRAGENYX ANNOUNCES THE PUBLICATION OF A SUCCESSFUL 96-WEEK RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH CROSSOVER TREATMENT OF GENGLYCOS™ (ALSO KNOWN AS DTX401) AAV GENE THERAPY IN GSDIA IN THE JOURNAL OF INHERITED METABOLIC DISEASE

Reuters·09/01/2026 20:05:01

Please log in to view news